Wave Life Sciences, Inc. (WVE) · Oct 27, 2026 · Earnings
Beat — Revenue $13.2M vs ~$4.51M consensus; EPS $(0.30) vs $(0.34) consensus
Wave Life Sciences earnings beat available Q3 estimates on collaboration revenue, while clinical milestones remain on schedule and cash runway holds into 2028.
Wave is a clinical-stage RNA-medicine company building around three main value drivers: obesity drug WVE-007, RNA-editing therapy WVE-006 for AATD, and WVE-008 for PNPLA3 liver disease. Its recent operating story was already moving toward broader obesity trials, a potential registrational path for WVE-006, and external validation through GSK’s collaboration.
The quarter beats the available financial benchmark, but mostly because of collaboration revenue. Revenue was $13.2 million versus an available published consensus of roughly $4.51 million, while reported diluted EPS of $(0.30) was modestly better than the roughly $(0.34) consensus. The revenue upside is meaningful, but it is not evidence of recurring product sales: Wave remains a clinical-stage company, and the filing attributes the quarter’s revenue to its collaboration economics rather than commercial drug demand. The company said, “Revenue recognized was $13.2 million for the third quarter of 2026 as compared to $7.6 million in the prior year quarter.”
| Metric | Q3 2026 | Q3 2025 / consensus | Read |
|---|---|---|---|
| Revenue | $13.2M | $7.6M prior year / ~$4.51M consensus | Large beat, collaboration-driven |
| Diluted EPS | $(0.30) | $(0.32) prior year / ~$(0.34) consensus | Slight beat |
| Net loss | $(61.9)M | $(53.9)M prior year | Loss widened |
| R&D expense | $53.8M | $45.9M prior year | Pipeline investment increased |
| G&A expense | $25.4M | $18.1M prior year | Corporate costs increased |
| Cash, cash equivalents and marketable securities | $431.0M | $490.6M at June 30, 2026 | Lower quarter over quarter; runway unchanged |
The business story advances through execution, not a new clinical proof point. WVE-007’s Phase 2a monotherapy dosing is ongoing, its tirzepatide combination study has started, and the post-incretin maintenance study remains on track for the fourth quarter. WVE-006 planning has moved toward a potentially registrational trial after FDA feedback, while WVE-008’s CTA filing remains targeted for the fourth quarter. These are useful timetable confirmations, but most of the major direction was already disclosed in September and October, so the filing adds limited surprise. The release says, “Planning is underway for our potentially registrational trial of WVE-006 for AATD.”
The cash position remains sufficient for the current development plan, despite heavier spending. Wave ended September with $431.0 million in cash, cash equivalents and marketable securities, expects another $12 million GSK milestone in the fourth quarter, and still projects funding into Q3 2028. That reduces near-term financing pressure, but the balance is down from $490.6 million at June 30 as R&D and G&A spending rose year over year. The filing states, “Wave expects that its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into the third quarter of 2028.” 〔0〕
The next meaningful test is clinical and strategic, not the income statement. Wave expects WVE-007 data from the 600 mg cohort in Q4 and plans to host Research Day on November 4, where it will detail the platform and WVE-008 opportunity. Those events matter more to the underlying biotech story than this quarter’s revenue beat, because they can provide evidence on whether the pipeline is translating from scheduled development into differentiated clinical value.
Bottom line: This is a modestly positive earnings print: the financial beat is large but collaboration-driven, while the pipeline continues to hit planned milestones without delivering a fresh efficacy readout. The filing supports Wave’s funded execution story, but does not fundamentally re-rate the clinical thesis on its own.
Research Day, November 4, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!